Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma
- PMID: 8104906
- DOI: 10.1002/ijc.2910550407
Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma
Abstract
To investigate the role of the p53 tumor-suppressor gene in the development of human melanoma, loss of heterozygosity (LOH) of p53 was studied in 46 cases of melanoma by a polymerase-chain-reaction/restriction-fragment-length polymorphism (PCR/RFLP) analysis, and p53 mutations were assessed in 51 cases of melanoma by a polymerase-chain-reaction/single-strand-conformation polymorphism (PCR/SSCP) analysis. Frozen tumors and paraffin samples were used in the study. We were not able to detect any allelic loss in 12BstUI informative cases or any single mutation in exons 5 to 8 of the p53 gene. Our results, together with other findings at the DNA level, suggest that the p53 gene appears not to be commonly involved in the development of melanoma, at least by its most frequent mechanisms of deletion of one allele and/or mutation in the other.
Similar articles
-
p53 expression, mutation, and allelic deletion in ovarian cancer.J Pathol. 1994 Nov;174(3):159-68. doi: 10.1002/path.1711740304. J Pathol. 1994. PMID: 7823248
-
Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.Cancer Res. 1993 Apr 15;53(8):1883-8. Cancer Res. 1993. PMID: 8385572
-
Chromosome 17 allelic loss and NF1-GRD mutations do not play a significant role as molecular mechanisms leading to melanoma tumorigenesis.J Invest Dermatol. 1996 Mar;106(3):432-6. doi: 10.1111/1523-1747.ep12343578. J Invest Dermatol. 1996. PMID: 8648172
-
Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7. Adv Exp Med Biol. 1997. PMID: 9321930 Review.
-
Genetic alterations in non-melanoma skin cancer.J Invest Dermatol. 1994 Dec;103(6):747-50. doi: 10.1111/1523-1747.ep12412256. J Invest Dermatol. 1994. PMID: 7798610 Review.
Cited by
-
Dual inactivation of RB and p53 pathways in RAS-induced melanomas.Mol Cell Biol. 2001 Mar;21(6):2144-53. doi: 10.1128/MCB.21.6.2144-2153.2001. Mol Cell Biol. 2001. PMID: 11238948 Free PMC article.
-
Establishment and characterization of a primary and a metastatic melanoma cell line from Grey horses.In Vitro Cell Dev Biol Anim. 2014 Jan;50(1):56-65. doi: 10.1007/s11626-013-9678-1. Epub 2013 Aug 28. In Vitro Cell Dev Biol Anim. 2014. PMID: 23982913
-
Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.J Transl Med. 2007 Apr 23;5:20. doi: 10.1186/1479-5876-5-20. J Transl Med. 2007. PMID: 17451606 Free PMC article.
-
E2F1-dependent oncogenic addiction of melanoma cells to MDM2.Oncogene. 2012 Feb 16;31(7):828-41. doi: 10.1038/onc.2011.277. Epub 2011 Jul 11. Oncogene. 2012. PMID: 21743494 Free PMC article.
-
From melanocytes to melanomas.Nat Rev Cancer. 2016 Jun;16(6):345-58. doi: 10.1038/nrc.2016.37. Epub 2016 Apr 29. Nat Rev Cancer. 2016. PMID: 27125352 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous